Next Level Education Acquires Summit Mortgage Training
FRANKLIN, Tenn.--(BUSINESS WIRE)-- Next Level Education (NLE), a provider of continuing education and training for the mortgage industry, announces it has acquired Summit Mortgage Training of Hanover, NJ. Andrea Gagliardi, founder of Summit, has joined the Next Level team as Director of Content Management.
'This acquisition was a strategic decision on our part to accelerate the growth of Next Level Education while expanding our access to mortgage professionals along the East Coast, empowering them with cutting-edge education options and industry-leading expertise,' said J.R. Huber, Co-Founder and CEO/President of NLE.
Debbie Gadberry, Co-Founder and COO/Senior Vice President of NLE, added, 'By acquiring Summit, we have immediately grown our content offerings to provide an even more robust and comprehensive training suite for the mortgage industry.'
Summit Mortgage Training was founded eight years ago by Gagliardi, who delivered pre-licensing education and NMLS Continuing Education (CE) courses as well as other training offerings throughout New Jersey, Pennsylvania, and Florida. Among the new courses that will be offered by NLE are 'Ninety Days to Impact!,' a 13-week coaching program for new loan officers designed to increase organizations and referral sources, and 'Mortgage Fundamentals,' an introductory course on the mechanics of loan originations.
To learn more about NLE and its innovative approach to professional development, go to https://nextleveled.com/.
About Next Level Education
An NMLS-approved provider, Next Level Education is redefining mortgage education and professional development. Leveraging modern tools like Adobe Learning Manager, it delivers impactful training and continuous education programs while keeping professionals informed with the latest industry news and updates. Its mission is to empower aspiring and experienced mortgage professionals with licensing and education courses that are accessible, interactive, and fun. For more information, call 615.899.5343 or visit www.nextleveled.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Senate budget plan wins final OK before panel
Senate budget writers gave their final, formal approval Tuesday for a two-year, $15.6 billion state budget proposal (HB 1) whose Republican architects called it a 'tough' plan that deals with a loss of billions in federal grants. 'The vast amount of it will make our state a better place, make it a powerhouse economically,' said state Sen. Tim Lang, R-Sanbornton. 'It was tough work, hard work. It was an excellent product for the state of New Hampshire." The two Democrats on the Senate Finance Committee praised their Republican colleagues for reversing several hundred million dollars of cuts made in the House-approved budget. But they said they voted against the budget plan for a lack of spending on housing and child care and for raising costs for working families, including a new health care premium for many families on Medicaid and the Children's Health Insurance Program. 'The Senate has made improvements to the budget that the House sent us. I don't think we can confuse 'better' with 'adequate,'' said Senate Deputy Democratic Leader Cindy Rosenwald of Nashua. 'This bill does nothing to lower costs for Granite Staters. In fact, it raises costs in many ways.' The panel approved by the same 6-2 vote a budget trailer bill (HB 2) that makes more than 260 changes in state law needed to carry out the budget priorities. 'This was a difficult road to go down. We were able to restore a lot of what the House had taken out,' said Senate Majority Leader Regina Birdsell, R-Hampstead. Senate President Sharon Carson, R-Londonderry, served on a budget committee for the first time in her 21 years in the Legislature. 'Over the last two biennium (four years), we had a lot of money, most of it an infusion of cash from the federal government," Carson said. "We spent that money and were smart about how we spent it, but it is gone. It is gone and now we have to go back to the New Hampshire way of living within our means." Finance Chairman James Gray, R-Rochester, noted the committee's first actions erased House cuts in payments to Medicaid providers and in services for mental health and people with developmental disabilities. 'This is a tight budget year, and that means we have to make tough choices with limited state dollars. Our focus has been on targeted state spending on New Hampshire's most vulnerable populations,' Gray said. The two-year Senate plan includes $67 million more in state aid to the University System of New Hampshire than the House budget. But Sen. Dan Innis, R-Bradford, a professor at the University of New Hampshire, said the $85 million a year in the Senate budget looks small, since the state was giving the University System $100 million a year in 2006. 'We need to start viewing both of these entities as investments in our future rather than spending,' Innis said. 'The $100 million every year, inflation-adjusted would be $166 million; we're spending $85 million, which is half. That's just embarrassing — it just is.' +++ What's Next: The full Senate votes on the recommended budget on Thursday. Prospects: A House-Senate conference committee will meet later this month to seek a compromise between the two spending bills. klandrigan@
Yahoo
an hour ago
- Yahoo
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability profile Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne HONG KONG, June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264). The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat and placebo arms. Table 1 summarizes some of baseline characteristics. Primary, key secondary, and secondary endpoints can be found in Table 2. Primary endpoints included the percent treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12), the percent reduction from baseline in total lesion count, and the percent reduction from baseline in inflammatory lesion count. At week 12, percent treatment success was 33.2% compared to 14.6% for placebo, p<0.0001, percent reduction from baseline in total lesion count was 57.4% compared to 35.4% for placebo, p<0.0001, and percent reduction from baseline in inflammatory lesion count was 63.5% compared to 43.2% for placebo, p<0.0001. The key secondary endpoint, percent reduction from baseline in non-inflammatory lesion count at week 12, was 51.9% compared to 28.9% for placebo, p<0.0001. Denifanstat demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat and placebo. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat-treated patients versus 2.9% in the placebo group; 5.9% dry eye in denifanstat-treated patients versus 3.8% in the placebo group). All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs (SAEs). No deaths were reported. The mechanisms of action of denifanstat for the treatment of acne are (1) direct inhibition of facial sebum production, through inhibition of de novo lipogenesis (DNL) in human sebocytes; and (2) inhibition of inflammation, through decreasing cytokine secretion and Th17 differentiation. Denifanstat's unique mechanism of action directly reduces one of the main underlying causes of acne which is the overproduction of sebum. This makes denifanstat unique as most other acne treatments do not treat the underlying cause of the condition. "We are extremely pleased with the topline results of our Phase III trial. Denifanstat tablets demonstrated impressive efficacy beyond treatment success, showing significant reductions in total lesion count, inflammatory lesion count, and non-inflammatory lesion count. We are excited to be submitting this innovative treatment with the China National Medical Products Administration (NMPA) soon." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. Table 3 highlights the excellent efficacy of denifanstat in a non-head-to-head comparison to other commonly used oral and topical acne treatments. Denifanstat demonstrated its exceptional efficacy across multiple key metrics compared to sarecycline, doxycycline and clascoterone cream. With regard to the placebo-adjusted percent treatment success and the placebo-adjusted percent reduction from baseline in inflammatory lesion count, denifanstat was 98% and 30% more effective than sarecycline, respectively, 178% and 178% more effective than doxycycline, respectively, and 60% and 59% more effective than clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in total lesion count, denifanstat was 189% and 85% more effective than doxycycline and clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in non-inflammatory lesion count, denifanstat was 411% and 102% more effective than sarecycline and clascoterone cream, respectively. Denifanstat has the potential to be a first-in-class, once-daily, oral acne therapeutic, potentially offering both exceptional efficacy and patient compliance with a favorable safety and tolerability profile. Compared to other oral acne treatments, denifanstat provides outstanding efficacy with excellent safety. There is no potential for antibiotic resistance or off target effects which can occur with tetracycline derivatives and no reported denifanstat-related severe AEs such as hepatotoxicity, hearing impairment and depression which are seen with isotretinoin. Denifanstat should also provide better adherence to treatment compared to topical therapies: an estimated 30% to 40% of patients do not adhere to their topical treatments[1]. Denifanstat is licensed from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China. "The Phase III clinical trial results for denifanstat are highly encouraging. The data demonstrate statistically significant improvements in treatment outcomes for moderate-to-severe acne patients, with percent treatment success of 33.2%, total lesion count reduction of 57.4% from baseline, inflammatory and non-inflammatory lesion counts decreasing by 63.5% and 51.9%, respectively, while maintaining a favorable safety and tolerability profile. Denifanstat's first-in-class mechanism targeting FASN directly addresses a key cause for acne, establishing it as a groundbreaking therapeutic approach in acne treatment." said Prof. Leihong Xiang, Chief Physician of Dermatological Department, Huashan Hospital, Fudan University, Executive Deputy Director of Institute of Dermatology, Fudan University, Deputy Director of Dermatology Division of Chinese Medical Doctor Association and principal investigator of denifanstat Phase III trial for moderate to severe acne. [1] Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055. Table 1. Baseline characteristics of Phase III trial of denifanstat Baseline characteristics 50 mg denifanstat, oral, oncedaily (n=240) Placebo, oral, once daily (n=240) Total lesion count 102.2 102.1 Inflammatory lesion count 42.1 43.1 IGA=3 (moderate), % 85.8 85.8 IGA=4 (severe), % 14.2 14.2 Table 2. Efficacy endpoints of 50 mg denifanstat oral, once daily at week 12 versus placebo (intent-to-treat, ITT, analysis) Efficacy endpoints (1) 50 mg denifanstat, oral, once daily (n=240) Placebo, oral,once daily (n=240) Placebo adjusted p value Percent treatment success (2) (primary endpoint) 33.2 14.6 18.6 <0.0001 Percent reduction from baseline in total lesion count (primary endpoint) 57.4 35.4 22.0 <0.0001 Percent reduction from baseline ininflammatory lesion count (primary endpoint) 63.5 43.2 20.3 <0.0001 Percent reduction from baseline in non-inflammatory lesion count (key secondary endpoint) 51.9 28.9 23.0 <0.0001 Absolute reduction from baseline intotal lesion count (secondary endpoint) 58.3 36.2 22.1 <0.0001 Absolute reduction from baseline in inflammatory lesion count (secondaryendpoint) 26.6 18.4 8.2 <0.0001 Notes: (1) All efficacy endpoints are least square means.(2) Treatment success is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12. Table 3. Denifanstat compared to other commonly used acne treatments (not head-to-head comparison) Category Denifanstat (n=240) Sarecycline(1) (n=1002) Doxycycline(2) (n=216) Clascoterone cream(3) (n=722) Baseline characteristics Total lesion count 102.2 72.4 71.7 103.6 Inflammatory lesion count 42.1 30.0 33.6 42.7 IGA=3 (moderate), % 85.8 85.2 93.5 82.7 IGA=4 (severe), % 14.2 14.9 6.5 17.3 Efficacy endpoints at week 12 Placebo-adjusted percenttreatment success 18.6 9.4 6.7 11.6 Placebo-adjusted percent reductionfrom baseline in total lesion count 22.0 NA 7.6 11.9 Placebo-adjusted percent reductionfrom baseline in inflammatorylesion count 20.3 15.6 7.3 12.8 Placebo-adjusted percent reduction from baseline in non-inflammatorylesion count 23.0 4.5 NA 11.4 Notes: (1) The sarecycline data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Moore, A., et al., J Drugs Dermatol 2018 Vol. 17 Issue 9 Pages 987-996. The non- inflammatory lesion count data are from FDA ( The doxycycline data at week 16 are from Moore, A., et al., J Drugs Dermatol 2015 Vol. 14 Issue 6 Pages 581-6.(3) The clascoterone cream (1%) data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Hebert. A, et al., JAMA Dermatology 2020 Vol. 156 Issue 6, DOI: 10.1001/jamadermatol.2020.0465. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter VozzoICR Healthcare443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Rand Paul, Mike Lee back Elon Musk over Trump-backed bill: ‘We can and must do better'
Republican Sens. Rand Paul (Ky.) and Mike Lee (Utah) are backing tech billionaire Elon Musk's criticism of the House-approved version of President Trump's agenda-setting megabill as it heads to the upper chamber for vetting. 'We can and must do better,' Paul wrote on the social platform X on Tuesday in response to Musk's post that slammed the One Big Beautiful Bill Act as a 'disgusting abomination.' Lee also chimed in, writing, 'The Senate must make this bill better,' in a reply to Musk. Musk's blistering critique of the measure touted by Trump and House Republican leaders comes just days after the end of Musk's White House role as a special adviser on government spending and de facto head of the Trump administration's Department of Government Efficiency (DOGE). 'I'm sorry, but I just can't stand it anymore. This massive, outrageous, pork-filled Congressional spending bill is a disgusting abomination,' Musk wrote on X, the platform that he owns. 'Shame on those who voted for it: you know you did wrong. You know it.' The massive tax and spending legislation would extend Trump's 2017 tax cuts and boost funding for border and defense priorities, while slashing spending on social safety net programs like Medicaid and food assistance. It narrowly passed the GOP-controlled House in May and is now up for Senate review. But Paul and other senators already have highlighted projections that it would add nearly $4 trillion to the national debt. Musk voiced tepid disapproval of the measure in a 'CBS Sunday Morning' interview over the weekend and said it 'it undermines the work that the DOGE team is doing.' 'I think a bill can be big, or it could be beautiful,' Musk said in the interview. 'I don't know if it could be both — my personal opinion.' But the more forceful rebuke marked a turn in his criticism and defense of his efforts to curb government waste. 'It will massively increase the already gigantic budget deficit to $2.5 trillion (!!!) and burden America citizens with crushingly unsustainable debt,' he wrote in a follow-up post on Tuesday. But the White House dismissed the criticism from Musk, who was a top donor to Trump's reelection campaign last fall. 'The president already knows where Elon Musk stood on this bill,' White House press secretary Karoline Leavitt told reporters during Tuesday's press briefing. 'It doesn't change his opinion.' Trump lashed out at Paul on Truth Social earlier Tuesday, accusing the Kentucky lawmaker of voting 'NO on everything' and 'never' having 'practical or constructive ideas.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
